Author: healthadmin

A shy teenager who dreams of becoming a nurse, the teenager has spent the past four years working with her mother and other relatives on a small farm pulling weeds, planting berries and removing old plastic sheets from fields. In 2023, the teenager said he and other workers worked in the fields without pay for more than a month. Some adults complained to their supervisors. “He kept saying, ‘I’ll pay you next week, I’ll pay you next week,'” she said. On some days, there were no toilets on site and workers were not provided with water or shade, she said.…

Servier, run by a nonprofit group, continues to make money with its IDH-mutant glioma treatment Volanigo, and the drug company is moving deeper into rare oncology with a new M&A strategy. Servier on Friday announced a definitive agreement to acquire DayOne Biopharmaceuticals, a commercial-stage company developing targeted therapies for childhood cancer and other diseases, for $21.50 per share in cash. In a March 6 release, the companies announced that the total transaction value, which is expected to close in the second quarter, is approximately $2.5 billion. The highlight of the deal is undoubtedly Day One’s Ojemda (toborafenib). It is a…

New research reveals that attention-deficit/hyperactivity disorder actually consists of at least two distinct brain structural subtypes, each with unique physical characteristics and behavioral symptoms. These structural differences suggest that patients may ultimately benefit from highly individualized diagnostic and therapeutic strategies based on their unique biology. The study was published in the journal General psychiatry. Attention-deficit/hyperactivity disorder is a highly common neurodevelopmental disorder that affects children and adolescents around the world. Patients typically exhibit a variety of symptoms that fall into categories such as inattention, hyperactivity, and impulsivity. Because the symptoms vary from child to child, medical professionals classify the symptoms…

Kyowa Kirin has decided to halt all clinical development of its OX40 drug following the occurrence of two new cancer cases. Sanofi has committed up to $1.5 billion for worldwide rights to Sino Biopharm’s first-in-class JAK/ROCK inhibitor with potential for graft-versus-host disease. Based on strong early-stage data in prostate cancer, BioNTech is advancing its B7-H3 antibody-drug conjugate licensed from DualityBio to Phase 3. 1. New cancer cases prompt Kyowa to cancel late-stage autoimmune disease program Kyowa Kirin has decided to halt all clinical development of its anti-OX40 drug, approximately one month after Amgen terminated its partnership with the company regarding…

Almost a century ago, astronomer Edwin Hubble discovered that nearly all galaxies are moving away from the Milky Way. This observation became the basis of modern cosmology, as it provided important evidence that the universe was expanding and that it began with a big bang. But even in Hubble’s time, astronomers knew that this pattern was not universal. One notable exception is the neighboring Andromeda galaxy, which is moving toward the Milky Way at about 100 kilometers per second. For about 50 years, scientists have puzzled over another related mystery. With the exception of Andromeda, most large galaxies near us…

PFAS, toxic “forever chemicals” linked to cancer and other serious health problems, were detected in all produce samples tested in a new study of vegetables purchased from Long Island farms, alarming researchers and environmental advocates who say the results point to a broader contamination problem in soil, water and food. “This is not an agricultural issue. This is a social issue,” Adrian Esposito, executive director of the Citizens’ Campaign for the Environment, said during a Zoom presentation about the study Thursday. “We’re not blaming the farmers.” Throughout his presentation, Esposito emphasized that farmers did not cause the pollution and that…

The design of modern research and development labs may need to be rethought. Artificial intelligence and automation are changing the way science is done, but many of the physical spaces in which research takes place are built on decades-old assumptions. In this episode of “The Top Line,” Fierce Life Sciences & Healthcare Editor-in-Chief Ayla Ellison speaks with Ryley Poblete, Gensler Global Science Practice Area Leader, about how automation, data, and new research workflows are impacting lab design. As computational scientists, engineers, and automated systems become more central to research teams, organizations are rethinking how labs should be configured to support…

Outstanding trial results for the combination of Tekvayli and Darzalex Faspro in previously treated relapsed or refractory multiple myeloma have earned Johnson & Johnson the third super-accelerated approval granted to the company under the FDA Commissioner’s National Priority Voucher (CNPV) testing program. In addition to the combination approval, which specifically targets patients who have received at least one type of therapy, including a proteasome inhibitor and an immunomodulator, the FDA also gave Tekvayli a bonus label update that converts the accelerated approval it received in 2022 into a traditional approval. The agency determined in a release that J&J’s Phase 3…

Recent research published in current psychology This provides evidence that employees who believe they are physically attractive are more likely to be active in the workplace and share their ideas. This increase in trust in the workplace appears to depend on the belief that appearance is an important social asset that gives people more influence. The results of this study suggest that individuals’ internal feelings about their own physical attractiveness may function as a hidden psychological resource in professional settings. Past research has shown that people who are judged to be more attractive by others tend to receive higher salaries…

The Buck Institute on Aging today announced the launch of Healthspan Horizons. This is a new initiative designed to address one of modern medicine’s most pressing challenges: how to measure, understand, and extend healthy lifespan (years of healthy life). People are living longer, but too much of that extra life is spent managing chronic diseases. In other words, healthy life expectancy (the number of years of healthy life lived) is not keeping up. Growing evidence suggests that many aspects of healthy aging are modifiable, with consequential implications for people, health systems, and economies. What is missing is the infrastructure to…